Trial Profile
Phase II study Evaluate Long-Term effects of Radotinibin in patients with Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Bcr-Abl1 Tkis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2017
Price :
$35
*
At a glance
- Drugs Radotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 25 Jun 2017 36-Month follow-up results presented at the 22nd Congress of the European Haematology Association
- 30 Oct 2015 New trial record